Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Melanoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Large Cell 1Breast Neoplasms 1Blast Crisis 1

Interventions

pembrolizumab 9Carboplatin 9Docetaxel 8Paclitaxel 6Nivolumab 6Cisplatin 5Gemcitabine 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4osimertinib 3fludarabine 3aldesleukin 3Radiotherapy 3Pemetrexed 3Erlotinib Hydrochloride 3Cyclophosphamide 3motexafin gadolinium 2figitumumab 2cemiplimab 2brigatinib 2atezolizumab 2alpha-2'-deoxythioguanosine 2Taxes 2Radiosurgery 2Ipilimumab 2Interleukin-2 2Crizotinib 2Bevacizumab 2vistusertib 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × tanespimycin × Thoracic × Clear all
NCT01362400 2014-05-19

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Infinity Pharmaceuticals, Inc.

Phase 2 Completed
226 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡